StreetInsider.com News Articles

Form SCHEDULE 13G Avalo Therapeutics, Inc. Filed by: Commodore Capital LP

Thu, 18 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260618/26666518.html

Form 8-K Avalo Therapeutics, Inc. For: Jun 16

Tue, 16 Jun 2026 07:18:00 -0400

si-local-file:///var/storage/secattach/20260616/26650383.html

AVALO Therapeutics adds anti-IL-1β antibody AVTX-010 to pipeline

Tue, 16 Jun 2026 07:02:58 -0400

Avalo Therapeutics, Inc. (NASDAQ: AVTX) announced the advancement of AVTX-010, an engineered anti-IL-1β monoclonal antibody, into its pipeline, with an Investigational New Drug application planned for the first half of 2027.

The company said AVTX-010 is designed to extend dosing intervals compared to its lead asset, abdakibart, and is being considered for development in hidradenitis suppurativa as well as additional inflammatory disorders. Avalo also stated the new molecule has the potential to strengthen its intellectual property position.

Chief Executive Officer Garry Neil, MD, said the decision follows topline Phase 2 data from the abdakibart LOTUS trial and engagement with the U.S. Food

AVALO Therapeutics adds anti-IL-1β antibody AVTX-010 to pipeline

Tue, 16 Jun 2026 07:02:58 -0400

Chief Executive Officer Garry Neil, MD, said the decision follows topline Phase 2 data from the abdakibart LOTUS trial and engagement with the U.S. Food

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Tue, 16 Jun 2026 07:00:00 -0400

IND submission for AVTX-010 planned for the first half of 2027

WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody (mAb) with the potential for development in hidradenitis suppurativa (HS) as well as additional inflammatory disorders.

“Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1β pathway, we believe developing a long-acting next-generation molecule

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Tue, 16 Jun 2026 07:00:00 -0400

IND submission for AVTX-010 planned for the first half of 2027

“Building on the strength of our abdakibart Phase 2 LOTUS topline data and our conviction in the IL-1β pathway, we believe developing a long-acting next-generation molecule

Form 4 Avalo Therapeutics, Inc. For: Jun 10 Filed by: Riley Jennifer

Fri, 12 Jun 2026 16:43:00 -0400

si-local-file:///var/storage/secattach/20260612/26641602.html

Form 4 Avalo Therapeutics, Inc. For: Jun 10 Filed by: VARKI PAUL

Fri, 12 Jun 2026 16:41:00 -0400

si-local-file:///var/storage/secattach/20260612/26641573.html

Form 4 Avalo Therapeutics, Inc. For: Jun 10 Filed by: Sullivan Christopher Ryan

Fri, 12 Jun 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260612/26641499.html

Form 4 Avalo Therapeutics, Inc. For: Jun 10 Filed by: Doyle Mittie

Fri, 12 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260612/26641280.html

Form 8-K Avalo Therapeutics, Inc. For: Jun 11

Fri, 12 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260612/26640766.html

BofA Securities Starts Avalo Therapeutics Inc. (AVTX) at Buy

Fri, 12 Jun 2026 05:16:53 -0400

BofA Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $35.00.

The analyst comments "We initiate coverage of Avalo with a Buy rating and $35 PO, with lead drug abdakibart now a cleaner, single-asset immunology story after positive phase 2 data in hidradenitis suppurativa, or HS, a common inflammatory skin disease. Abdakibart could offer more convenient monthly dosing and superior disease impact vs competing drugs if repeated in phase 3 studies starting 1H27e. We see the investment case as straightforward: a differentiated IL-1β antibody in HS, a large undertreated

BofA Securities Starts Avalo Therapeutics Inc. (AVTX) at Buy

Fri, 12 Jun 2026 05:16:53 -0400

BofA Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $35.00.

BofA Securities Starts Avalo Therapeutics Inc. (AVTX) at Buy

Fri, 12 Jun 2026 05:16:53 -0400

BofA Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $35.00.

BofA Securities Starts Avalo Therapeutics Inc. (AVTX) at Buy

Fri, 12 Jun 2026 05:16:53 -0400

BofA Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Buy rating and a price target of $35.00.

Form 8-K Avalo Therapeutics, Inc. For: Jun 02

Mon, 08 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260608/26617623.html

Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: FMR LLC

Fri, 05 Jun 2026 10:13:00 -0400

si-local-file:///var/storage/secattach/20260605/26609294.html

Form 4 Avalo Therapeutics, Inc. For: Jun 02 Filed by: Heffernan Michael Thomas